- Home
- FULC vs GEVO Comparison
FULC vs GEVO Comparison
Compare FULC & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FULC | GEVO |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.1M | 470.1M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FULC | GEVO |
|---|---|---|
| Price | $14.60 | $2.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $15.88 | $8.13 |
| AVG Volume (30 Days) | 2.2M | ★ 3.1M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $120,932,000.00 |
| Revenue This Year | N/A | $927.85 |
| Revenue Next Year | N/A | $12.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2752.05 | 675.75 |
| 52 Week Low | $2.32 | $0.92 |
| 52 Week High | $15.74 | $2.98 |
Technical Indicators
Market Signals| Indicator | FULC | GEVO |
|---|---|---|
| Relative Strength Index (RSI) | 72.49 | 56.11 |
| Support Level | $8.63 | $1.83 |
| Resistance Level | $15.74 | $2.42 |
| Average True Range (ATR) | 1.23 | 0.11 |
| MACD | 0.26 | 0.03 |
| Stochastic Oscillator | 82.56 | 72.88 |
Price Performance
Historical ComparisonAbout FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.